Cargando…

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

INTRODUCTION: Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). METHODS: A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for 12 weeks on primary safety and pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagan, Fernando L., Torres‐Yaghi, Yasar, Hebron, Michaeline L., Wilmarth, Barbara, Turner, R. Scott, Matar, Sara, Ferrante, Dalila, Ahn, Jaeil, Moussa, Charbel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157583/ https://www.ncbi.nlm.nih.gov/pubmed/35662832 http://dx.doi.org/10.1002/trc2.12296

Ejemplares similares

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
por: Fowler, Alan J., et al.
Publicado: (2021)

4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
por: Fowler, Alan, et al.
Publicado: (2020)

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
por: Turner, Raymond S., et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
por: Pagan, Fernando. L., et al.
Publicado: (2020)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
por: Anderson, Karen E., et al.
Publicado: (2022)

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
por: Hebron, Michaeline L., et al.
Publicado: (2014)

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
por: Lonskaya, Irina, et al.
Publicado: (2014)

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
por: Stevenson, Max, et al.
Publicado: (2023)

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
por: Liu, Xiaoguang, et al.
Publicado: (2021)

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
por: Desforges, Nicole M., et al.
Publicado: (2012)

Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
por: Peterson, Bethany, et al.
Publicado: (2019)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice
por: Liu, Xiaoguang, et al.
Publicado: (2022)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
por: Fowler, Alan J., et al.
Publicado: (2019)

An Adaptive Measure of Visuospatial Impairment in Dementia with Lewy Bodies
por: Phillips, Joseph R., et al.
Publicado: (2022)

Sialorrhea in Parkinson’s Disease
por: Isaacson, Jonathan, et al.
Publicado: (2020)

Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria
por: Phillips, Joseph R., et al.
Publicado: (2022)

Incident pulmonary arterial hypertension associated with Bosutinib
por: Yo, Shaun, et al.
Publicado: (2020)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
por: Carneiro, Priscila J., et al.
Publicado: (2017)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia
por: Matar, Elie, et al.
Publicado: (2022)

Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
por: Segrelles, Carmen, et al.
Publicado: (2018)

Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies
por: Phillips, Joseph R., et al.
Publicado: (2021)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Neuroimaging in Lewy body dementia
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Microbleeds in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1n9nhqthqr6f7t8sjff9cipjns